Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin

Diabetes Care

Volumn 21, Issue 5, 1998, Pages 800-803

  Heise, Tim ^a   Weyer, Christian ^a   Serwas, Andreas ^a   Heinrichs, Sebastian ^a   Osinga, Johannes ^a   Roach, Paris ^c   Woodworth, Jim ^c   Gudat, Uwe ^b   Heinemann, Lutz ^a,d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d Med Einrichtungen Heinrich H   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN LISPRO; NEUTRAL PROTAMINE LISPRO INSULIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG STABILITY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; INSULIN TREATMENT; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; PREFORMULATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; C-PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, ISOPHANE; MALE; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 0031736143     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.5.800     Document Type: Article

References (10)

1. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37:736-744, 1988
2. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
3. Heinemann L, Heise T, Jorgensen LN, Starke AAR: Action profile of the rapid acting insulin analogue B28Asp. Diabet Med 10:535-539, 1993
4. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684, 1996
5. DeFelippis MR, Bakaysa DL, Youngman KM, Radziuk J, Frank BH: Preparation and characterization of neutral protamine lispro (NPL) suspension (Abstract). Diabetes 45 (Suppl. 2):74A, 1996
6. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754, 1996
7. Bender R, Heinemann L: Fitting nonlinear regression models with correlated errors to individual pharmacodynamic data using SAS software. J Pharmacohinet Biopharm 23:87-100, 1995
8. Radziuk J, Bradley BJ, Welsh L, De Fellipis MR, Roach P: Neutral protamine lispro: activity profile of s.c. administration with and without admixture of soluble lispro (Abstract). Diabetologia 39 (Suppl. 1):A224, 1996
9. Woodworth JR, Howey DC, Bowsher RR, Lutz S, Santa PF, Brady P: [Lys(B28), Pro(B29)] human insulin (K): dose-ranging vs. Humulin R (H) (Abstract). Diabetes 42 (Suppl. 1):54A, 1993
10. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli GB: Effects of the short-acting insulin analog [Lys(B28),Pro(Pro)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-951, 1996